Researchers Submit Patent Application, "Yeast-Based Vaccines", for Approval (USPTO 20230148096).

The genetically-engineered cell for use of claim 48, wherein the coronavirus is SARS-CoV-2, MERS-CoV or SARS-CoV. "50. The genetically-engineered fungal cell of claim 17 or 18, wherein the cell targeting molecule is a molecule for targeting the genetically-engineered fungal cell and/or antigen to an immune cell. The genetically-engineered fungal cell of any one of claims 1-7, wherein the antigen is secreted from the fungal cell by the alpha-mating factor secretion pathway of the fungal cell. The genetically-engineered fungal cell of claim 1, wherein the coronavirus is SARS-CoV-2, MERS-CoV or SARS-CoV. "3. [Extracted from the article]